What labs are used to monitor liver rejection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 10, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

From the Guidelines

To monitor liver rejection, healthcare providers primarily use liver function tests (LFTs) including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and bilirubin levels, as these enzymes typically elevate during rejection episodes, with AST and ALT often rising first and most dramatically, as noted in the most recent study 1. The most critical labs for monitoring liver rejection include:

  • Alanine transaminase (ALT)
  • Aspartate transaminase (AST)
  • Alkaline phosphatase (ALP)
  • Bilirubin levels These labs are crucial because they reflect hepatocellular damage or bile flow impairment, which are indicative of liver rejection. Additionally, prothrombin time (PT) and international normalized ratio (INR) are also monitored as they reflect the liver's synthetic function, which can be affected during rejection episodes, as mentioned in 1. Complete blood counts and tacrolimus or cyclosporine blood levels are also regularly checked to ensure immunosuppression is adequate without toxicity, as discussed in 2. It's essential to note that while these labs provide valuable information, definitive diagnosis of rejection typically requires a liver biopsy, as stated in 2. Labs are usually monitored very frequently immediately post-transplant, then gradually decreased to monthly and eventually quarterly as the patient stabilizes, with any unexplained elevation in these parameters warranting immediate evaluation for possible rejection, as recommended in 2. The frequency of monitoring and the specific labs used may vary depending on the individual patient's needs and the transplant center's protocols, but the primary focus is always on preventing and detecting rejection to ensure the best possible outcomes for liver transplant patients, as emphasized in 2.

From the FDA Drug Label

Monitoring of tacrolimus blood concentrations in conjunction with other laboratory and clinical parameters is considered an essential aid to patient management for the evaluation of rejection, toxicity, dose adjustments, and compliance. Whole blood trough concentration range can be found in Table 1 Blood concentration monitoring is not a replacement for renal and liver function monitoring and tissue biopsies

The labs used to monitor liver rejection include:

  • Tacrolimus blood concentrations: whole blood trough concentrations are recommended to assist in the clinical evaluation of toxicity and efficacy failure
  • Renal function monitoring: to evaluate the risk of nephrotoxicity
  • Liver function monitoring: to evaluate the risk of hepatic impairment
  • Tissue biopsies: to directly assess liver function and rejection 3

From the Research

Liver Rejection Labs

To monitor liver rejection, several labs and tests can be utilized. These include:

  • Liver biopsy, which remains the most widely used method for diagnosing allograft rejection following liver transplantation 4
  • Serum enzyme monitoring, such as serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and bilirubin levels 5
  • Doppler ultrasonographic (US) measurements, including portal blood velocity (PBV) and splenic pulsatility index (SPI) 6
  • Quantification of dd-cfDNA and DSA, which show potential in indicating the status of allograft rejection and aiding in immunosuppression modulation 4
  • mRNA microarray profiling of differentially expressed genes, as well as characterization of cytokine responses and immunophenotypic shifts following liver transplantation, which may predict and recognize rejection events 4

Lab Test Interpretation

When interpreting lab results, it is essential to consider the following:

  • Hepatocellular injury is defined as disproportionate elevation of AST and ALT levels compared with alkaline phosphatase levels 5
  • Cholestatic injury is defined as disproportionate elevation of alkaline phosphatase level as compared with AST and ALT levels 5
  • Elevated conjugated bilirubin implies hepatocellular disease or cholestasis 5
  • The degree of elevation of ALT and/or AST in the clinical setting helps guide the evaluation 5

Additional Tests

In some cases, additional tests may be necessary to evaluate liver function and diagnose rejection, such as:

  • Viral hepatitis testing (A, B, and C) 5
  • Assessment for nonalcoholic fatty liver disease and alcoholic liver disease 5
  • Screening for hereditary hemochromatosis, autoimmune hepatitis, Wilson's disease, and alpha-1 antitrypsin deficiency 5
  • Liver biopsy, which may be considered when serologic testing and imaging fail to elucidate a diagnosis, to stage a condition, or when multiple diagnoses are possible 5

References

1
Guideline

acr appropriateness criteria® abnormal liver function tests.

Journal of the American College of Radiology, 2023

5
Research

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.

The American journal of gastroenterology, 2017

Related Questions

What is the most appropriate next step in evaluating and managing a 15‑year‑old male with persistent elevated hemoglobin, mildly increased reticulocyte count, mildly elevated aspartate aminotransferase, alanine aminotransferase, and gamma‑glutamyl transferase, normal alkaline phosphatase and bilirubin, mildly elevated ferritin, normal abdominal ultrasound without fatty liver or splenomegaly, and a family history of non‑alcoholic cirrhosis?
What is the likely cause and recommended work‑up for a persistent total bilirubin of 2.7 mg/dL in a 15‑year‑old female with normal liver function tests?
In a 16‑year‑old male with mild scleral and peripheral icterus, AST 36 U/L (upper normal), total bilirubin 47 µmol/L, normal complete blood count and liver panel, and no abdominal pain, what is the most likely diagnosis and recommended management?
In a 20‑year‑old male chronic alcoholic presenting with icterus, elevated total bilirubin, elevated direct and indirect bilirubin, markedly elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT), normal total protein, albumin, hemoglobin, white blood cell count and platelet count, neutrophil percentage 45.8% and lymphocyte percentage 41.8%, what is the diagnosis and the appropriate treatment with dosages?
In a 14-year-old with incidentally discovered mildly elevated liver function tests that have decreased but remain above normal after two months, what is the appropriate evaluation and management?
Can cephalosporins (antibiotics) cause neutropenia (low neutrophil count)?
What is the further workup and management for an infant with neonatal hypocalcemia (low calcium levels) and hyperphosphatemia (elevated phosphate levels)?
What is the recommended follow-up schedule for a patient starting an antidepressant, such as a selective serotonin reuptake inhibitor (SSRI), for postpartum depression?
How is orthostatic hypertension managed?
Is Fetal Fibronectin (FFN) testing indicated for a patient at 35 weeks of gestation?
Can people cough after having a lung transplant?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.